Q3 2025 · 13F-HR
Frazier Life Sciences Management, L.P.holdings as filed
Filed 2025-11-14 · accession 0001892134-25-000012
$3.34B
Reported value
47
Positions
2025-09-30
Period end
The Brief · Frazier Life Sciences Management, L.P. · Q3 2025
AI · grounded in 13F
Frazier Life Sciences Management, L.P. established a new position in MIRM valued at $498.2M. The fund also initiated new stakes in NAMS for $475M and VRNA for $361.1M. Additional new positions include BBIO at $199.7M and ARQT at $186.1M. Total assets under management stand at $3.3B across 47 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $498.2M | 14.9% | 6,795,121 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $475.0M | 14.2% | 16,701,956 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $361.1M | 10.8% | 3,383,950 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $199.7M | 5.98% | 3,845,457 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $186.1M | 5.58% | 9,874,511 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $146.7M | 4.40% | 12,466,489 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $121.5M | 3.64% | 688,460 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $118.4M | 3.55% | 4,567,274 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $116.4M | 3.49% | 6,652,013 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $95.1M | 2.85% | 1,438,534 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $93.9M | 2.81% | 10,259,409 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $69.4M | 2.08% | 1,167,527 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $61.4M | 1.84% | 5,039,867 | Common | SOLE |
| 98887Q104 | ZLAB | ZAI LAB LTD | $55.1M | 1.65% | 1,627,320 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $51.4M | 1.54% | 1,279,754 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $49.6M | 1.48% | 22,729,436 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $48.9M | 1.47% | 890,445 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $46.6M | 1.40% | 997,455 | Common | SOLE |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC NE | $45.3M | 1.36% | 722,400 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $40.9M | 1.23% | 11,462,301 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $34.4M | 1.03% | 2,718,105 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $32.1M | 0.96% | 378,300 | Common | SOLE |
| 05153U107 | AURA | AURA BIOSCIENCES INC | $31.5M | 0.94% | 5,100,000 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $29.6M | 0.89% | 983,715 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $29.4M | 0.88% | 4,424,725 | Common | SOLE |
| 92025Y103 | VALN | VALNEVA SE | $28.0M | 0.84% | 2,291,666 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $27.2M | 0.82% | 625,000 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $26.5M | 0.79% | 133,333 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $21.0M | 0.63% | 700,647 | Common | SOLE |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PLC | $19.4M | 0.58% | 9,440,112 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $17.4M | 0.52% | 366,784 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $17.1M | 0.51% | 474,405 | Common | SOLE |
| 30052C107 | EOLS | EVOLUS INC | $16.2M | 0.48% | 2,630,665 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $14.7M | 0.44% | 1,953,547 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $14.0M | 0.42% | 384,782 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $13.1M | 0.39% | 613,837 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $12.2M | 0.37% | 1,413,280 | Common | SOLE |
| 045396207 | ASMB | ASSEMBLY BIOSCIENCES INC | $11.7M | 0.35% | 456,249 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $9.4M | 0.28% | 2,077,431 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $9.4M | 0.28% | 392,092 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $8.6M | 0.26% | 500,333 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $7.9M | 0.24% | 1,157,380 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $7.5M | 0.23% | 4,623,324 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $5.3M | 0.16% | 3,175,665 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $5.0M | 0.15% | 970,130 | Common | SOLE |
| 019770106 | ALLO | ALLOGENE THERAPEUTICS INC | $4.8M | 0.14% | 3,868,750 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $3.2M | 0.10% | 272,951 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.